VistaGen Therapeutics, Inc. EV/Sales

EV/Sales of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/Sales growth rates and interactive chart. Compares the total enterprise value of a company to its sales. It is a more accurate measure of business value, as it takes into account cash and debt on the balance sheet. A company with large cash holdings and no debt will show a significantly lower EV/S than P/S ratio.

Highlights and Quick Summary

Current EV/Sales of VistaGen Therapeutics, Inc. is 10.49 (as of March 30, 2017)
  • EV/Sales for the quarter ending December 30, 2020 was 27.11 (a 70.25% increase compared to previous quarter)
  • Year-over-year quarterly EV/Sales decreased by -93.31%
  • Annual EV/Sales for 2017 was 10.49 (a -96.64% decrease from previous year)
  • Annual EV/Sales for 2013 was 312.18 (a -48.53% decrease from previous year)
  • Annual EV/Sales for 2012 was 606.57 (a Infinity% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/Sales of VistaGen Therapeutics, Inc.

Most recent EV/Salesof VTGN including historical data for past 10 years.

Interactive Chart of EV/Sales of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. EV/Sales for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 27.11 15.92
2017 10.49
2016 18.33
2013 312.18
2012 405.28 606.57 606.57
2011 816.3 490.57 285.77 0.0 0.0
2010 0.0 0.0

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.